相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Laura C. Cappelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
Igor N. Ivashko et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
Checkpoint inhibitors and gastrointestinal immune related adverse events
Simon Pernot et al.
CURRENT OPINION IN ONCOLOGY (2016)
Endocrinological side-effects of immune checkpoint inhibitors
Francesco Torino et al.
CURRENT OPINION IN ONCOLOGY (2016)
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Frank B. Cortazar et al.
KIDNEY INTERNATIONAL (2016)
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
Michiel van der Vlist et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Clinical Images: Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment
Guillermo de Velasco et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Eosinophilic Fasciitis and Acute Encephalopathy Toxicity from Pembrolizumab Treatment of a Patient with Metastatic Melanoma
Leila Khoja et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Case of respiratory discomfort due to myositis after administration of nivolumab
Miri Yoshioka et al.
JOURNAL OF DERMATOLOGY (2015)
Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
Matthew M. K. Chan et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
Amanda D. Henderson et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2015)
Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade
Shirwa Sheik Ali et al.
JAMA DERMATOLOGY (2015)
Examination of Autoantibody Status and Clinical Features Associated With Cancer Risk and Cancer-Associated Scleroderma
Ami A. Shah et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion
Robert M. Conry et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis
A Doran Bostwick et al.
Journal for ImmunoTherapy of Cancer (2015)
Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease
Magnus Pedersen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Kidney injuries related to ipilimumab
Hassane Izzedine et al.
INVESTIGATIONAL NEW DRUGS (2014)
Ipilimumab in a patient with known Crohn's disease: To give or not to give?
Eric A. R. Gielisse et al.
JOURNAL OF CROHNS & COLITIS (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
Christine G. Joseph et al.
SCIENCE (2014)
Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4
Barbara L. Goldstein et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-I inhibition in a patient with metastatic cutaneous melanoma
Joshua S. Manusow et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Most Patients With Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1γ
David F. Fiorentino et al.
ARTHRITIS AND RHEUMATISM (2013)
Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
David R. Minor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy
Yuki Ichimura et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: A systematic review and meta-analysis
Ernesto Trallero-Araguas et al.
ARTHRITIS AND RHEUMATISM (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy
Yulia Bronstein et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Close Temporal Relationship Between Onset of Cancer and Scleroderma in Patients With RNA Polymerase I/III Antibodies
Ami A. Shah et al.
ARTHRITIS AND RHEUMATISM (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Gary Hunter et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2009)
Anti-CTLA4 Antibody-Induced Lupus Nephritis.
Fouad Fadel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
分享论文
